Bromocriptine is an ergot alkaloid dopamine D2 receptor agonist that has been used
extensively in the past to treat hyperprolactinaemia, galactorrhoea and Parkinsonism. It is …

Importance to the field: There is a large unmet need for new therapies to treat type 2
diabetes (T2DM) which reduce fasting and postprandial glucose without increasing insulin …

Bromocriptine mesylate quick-release was approved by the Food and Drug Administration
(FDA) in May 2009, for the treatment of type 2 diabetes. Bromocriptine is thought to act on …

Quick-release bromocriptine (bromocriptine-QR)(Cycloset) was approved in 2009 for the
treatment of type 2 diabetes. The exact anti-diabetic mechanism of action of bromocriptine …

Objective: To review the pharmacologic characteristics, safety, and efficacy of bromocriptine
mesylate for glycemic control in patients with type 2 diabetes mellitus. Data Sources: A …

An extended series of studies indicate that endogenous phase shifts in circadian neuronal
input signaling to the biological clock system centered within the hypothalamic …

Bromocriptine, a potent dopamine D2 receptor agonist, has been shown to reduce insulin
resistance, glucose intolerance and hyperlipidaemia in both numerous animal studies and …

Objectives: To provide an evidence-based practice overview on the clinical use of
bromocriptine-quick release (QR) across the natural history of type 2 diabetes mellitus …

D2-dopamine agonist that has been approved for the treatment of type 2 diabetes. Based on
animal and human studies, timed bromocriptine administration within 2 h of awakening is …

Objective To review available data on the efficacy and safety of bromocriptine-QR (BQR)
and to consider its role in the management of Type 2 diabetes mellitus (T2DM). Methods …